Similarly, the pretreatment of azacitidine and DNMT1 depletion sensitized metastatic castration-resistant prostate cancer cells to the cytotoxic chemotherapeutics cabazitaxel and docetaxel [31,32]. This evidence concerns the gene DNMT1 and prostate carcinoma.